V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation...
- Mechanism
- Curator reviewed
V1003 is an intranasal formulation of buprenorphine. Buprenorphine's analgesic effect is due to partial agonist activity at mu-opioid receptors. Buprenorphine is also a kappa-opioid receptor antagonist. The partial agonist activity means that opioid receptor antagonists (e.g., an antidote such as naloxone) only partially reverse the effects of buprenorphine. The binding to the mu and kappa receptors results in hyperpolarization and reduced neuronal excitability.
- Primary indication
- Investigated for use/treatment in pain (acute or chronic).Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with V1003, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account